Test Drug: Clinical Trials

35 trials of Test Drug, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed, 7 unknown, 5 not yet recruiting, 1 active not recruiting. 35 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 135Completed 22, Unknown 7, Not yet recruiting 5, Active not recruiting 1

Follow Test Drug: new trials by email Literature Review of Test Drug trials Research Report on Test Drug

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers
Test Drug, Reference Drug - Hypercholerolemia, Dyslipidemia
Phase 1CompletedAJU Pharm Co., Ltd.612026-08-062026-09-09
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions
Test Drug, Reference Drug - Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Phase 1Not yet recruitingAJU Pharm Co., Ltd.362026-07-012026-06-11
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions
Test Drug, Reference Drug - Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Phase 1CompletedAJU Pharm Co., Ltd.452026-06-272026-09-21
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia
Phase 1CompletedAJU Pharm Co., Ltd.412026-06-112026-07-10
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
CKD-215, D215 - Ovarian Cancer
Phase 1Not yet recruitingChong Kun Dang Pharmaceutical242026-06-012026-04-15
A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults
Comparator 1, Comparator 2, Test Drug - Type2 Diabetes Mellitus
Phase 1Not yet recruitingAJU Pharm Co., Ltd.502025-08-012025-06-24
A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study
Comparator 1, Comparator 2, Test Drug - Type2 Diabetes Mellitus
Phase 1Not yet recruitingAJU Pharm Co., Ltd.322025-08-012025-07-01
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults
Test Drug, Reference Drug - Dyslipidemia
Phase 1Active not recruitingAJU Pharm Co., Ltd.602025-05-242025-06-12
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
AD-120A, AD-120 - Gastroesophageal Reflux Disease (GERD)
Phase 1Not yet recruitingAddpharma Inc.482025-04-212025-04-08
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults
Test Drug, Reference Drug - Hypercholesterolemia
Phase 1CompletedAJU Pharm Co., Ltd.602025-03-292025-06-12
A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability
Test Drug (Eutropin Catridge, 48IU/Cartridge), Reference Drug (Eutropin, 4 IU/vial) - Healthy Volunteers
Phase 1CompletedLG Chem482025-01-132025-04-17
Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics
Vamorolone, Midazolam - Drug Interaction
Phase 1CompletedSanthera Pharmaceuticals182024-08-132025-12-15
A Phase 1 Study of EXT608 in Healthy Adults
EXT608, Placebo - Safety Issues
Phase 1CompletedExtend Biosciences Inc.242022-07-212025-02-04
Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model
IP2015, dose 1, IP2015, dose 2, Placebo - Pain
Phase 1UnknownInitiator Pharma242022-01-052022-01-06
A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
AD-214, AD-2141 - Gastroesophageal Reflux Disease
Phase 1CompletedAddpharma Inc.412021-11-012022-07-20
A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers
C52R1H Tab. and C52R2 Tab., AJU-C52L - Hypertension
Phase 1UnknownAJU Pharm Co., Ltd.602021-09-242021-10-14
A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers
C52R1M Tab. and C52R2 Tab., AJU-C52H - Hypertension
Phase 1UnknownAJU Pharm Co., Ltd.602021-09-172021-10-14
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers
Lixiana(D006), CKD-344 - Anticoagulant
Phase 1UnknownChong Kun Dang Pharmaceutical602021-04-272021-04-30
Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions
Duloxetine 60mg Test Drug Enteric Coated Granules, Duloxetine 60mg Reference Product Enteric Coated Granules - Bioequivalence
Phase 1CompletedLaboratorios Andromaco S.A.362021-02-272021-04-15
A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-845
D309, CKD-845 - Hypogonadism
Phase 1CompletedChong Kun Dang Pharmaceutical472020-11-162022-09-28

Showing 20 of 35. Sign in to see all of them.

Conditions studied

Dyslipidemias (4)  ·  Gastroesophageal Reflux (3)  ·  Hypertension (3)  ·  Cardiovascular Diseases (2)  ·  Diabetes Mellitus, Type 2 (2)  ·  Hypercholesterolemia (2)  ·  Diabetic Neuropathies (1)  ·  Gastritis (1)  ·  Hyperlipidemias (1)  ·  Hypogonadism (1)  ·  Neuralgia (1)  ·  Neuralgia, Postherpetic (1)  ·  Ovarian Neoplasms (1)  ·  Pain (1)

Sponsors

AJU Pharm Co., Ltd. (11)  ·  Chong Kun Dang Pharmaceutical (9)  ·  Addpharma Inc. (4)  ·  Pfizer (2)  ·  Atabay Kimya Sanayi Ticaret A.S. (1)  ·  Avilex Pharma (1)  ·  Boehringer Ingelheim (1)  ·  Extend Biosciences Inc. (1)  ·  GL Pharm Tech Corporation (1)  ·  Initiator Pharma (1)  ·  LG Chem (1)  ·  Laboratorios Andromaco S.A. (1)  ·  Santhera Pharmaceuticals (1)

Countries

South Korea (27)  ·  Brazil (1)  ·  Chile (1)  ·  Finland (1)  ·  Germany (1)  ·  Turkey (Türkiye) (1)  ·  United States (1)

Top investigators

Min-gul Kim (3)  ·  Seunghwan Lee, M.D.,Ph.D (2)  ·  Yook-Hwan Noh (2)  ·  An-Hye Kim, M.D., PhD. (1)  ·  Hyewon Chung, M.D., PhD. (1)  ·  In-Jin Jang, M.D.,Ph.D (1)  ·  Jang Hee Hong (1)  ·  Jeong-Yeol Park, Ph.D (1)  ·  Laura Hales, PhD (1)  ·  Michael Lissy, MD (1)  ·  Mika Scheinin, MD (1)  ·  Min-Gul Kim, Ph.D. (1)  ·  Min-gul Kim, M.D., PhD. (1)

NIH funding

R44DK107231 (1)